Trial Profile
Dapagliflozin therapy in Type 2 Diabetes Mellitus patients fasting in the month of Ramadan.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2016
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 16 Sep 2016 Primary endpoint (Mean change in body weight at week 6 (Ramadan fasting month) and week 12) has been met according to the results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes .
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 15 Mar 2016 New trial record